Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | MMP1 | P03956 | 2/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21820776 | 0.96 | TDP1 (0.74) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL11314750 | 0.91 | TDP1 (0.72) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL6048301 | 0.89 | TDP1 (0.69) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL11794251 | 0.89 | TDP1 (0.71) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL21132037 | 0.89 | TDP1 (0.71) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL11009788 | 0.88 | TDP1 (0.71) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL2112591 | 0.88 | TDP1 (0.74) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL21100581 | 0.87 | TDP1 (0.70) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL21100582 | 0.87 | TDP1 (0.70) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL1073813 | 0.87 | TDP1 (0.67) | TDP1LMNAADRA2ACNR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2020-03-19 | — | — | US | disclosed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | disclosed |
| EP-1188735-B1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL CO (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040152592-A1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY, LIMTED | 2004-08-05 | — | — | US | disclosed |
| US-6703528-B2 | CATALYTIC OXIDATION OF OLEFIN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-03-09 | — | — | US | disclosed |
| EP-1188735-A1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-20020025906-A1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | TDP1 3519/4885LMNA 3363/4885ADRA2A 2312/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | TDP1 3519/4885LMNA 3363/4885ADRA2A 2312/4885 |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | TDP1 3519/4885LMNA 3363/4885ADRA2A 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.